Our editorial recommendations are based on research, product quality, performance, and value
and consulting fees from Faeth Therapeutics, Vividion Therapeutics Calithera, ONCO0 Inc and Tohoku University outside the submitted work
Clinically, BCS can reduce serum levels of hs-CRP, NSE, and S-100 protein, effectively reducing central nervous system inflammatory responses, alleviating neurological damage, improving medium-to-long-term prognosis, and possessing high clinical utility (Wang et al., 2021)
KimSBJoYHLiuQAhnJHHongIPHanSMet al
If I asked, how many here are politicians
Arthroscopy, volume 0, September 9, 2024